{"preliminary_commentary":{"by_channel":{"x_thread":136,"youtube":86,"podcast":52},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT03876769\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"name":"CASSIOPEIA","nct_id":"NCT03876769","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=cassiopeia-nct03876769. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"CASSIOPEIA","arms":[{"description":"Based on the subject's weight one of two possible dose ranges will be prepared for the subject:\n\nSubjects ≤ 50 kg: 0.2 to 5.0 x 10(6) CAR-positive viable T cells per kg body weight\n\nOR\n\nSubjects \\> 50 kg: 0.1 to 2.5 x 10(8) CAR-positive viable T cells","label":"Single dose of CTL019","type":"EXPERIMENTAL"}],"collaborators":["Children's Oncology Group"],"completion_date":{"date":"2027-10-19","type":"ESTIMATED"},"conditions":["B-Cell Acute Lymphoblastic Leukemia"],"enrollment":{"count":121,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"CTL019","otherNames":[],"type":"BIOLOGICAL"}],"last_update":"2026-08-19","lead_sponsor":"Novartis Pharmaceuticals","official_title":"A Phase II Trial of Tisagenlecleucel in First-line High-risk (HR) Pediatric and Young Adult Patients With B-cell Acute Lymphoblastic Leukemia (B-ALL) Who Are Minimal Residual Disease (MRD) Positive at the End of Consolidation (EOC) Therapy","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2027-10-19","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Disease Free Survival (DFS) rate without censoring for new anticancer therapy, including Stem Cell Transplantation (SCT) while in remission","timeFrame":"5 years after tisagenlecleucel infusion"},{"measure":"Overall Survival (OS) rate","timeFrame":"4 years after tisagenlecleucel"}],"references":[{"citation":"Davis KL, Yao CC, Zimmerman JAO, Rau RE. Immunotherapy in B-Cell Acute Lymphoblastic Leukemia. J Natl Compr Canc Netw. 2025 Dec;23(12):e257067. doi: 10.6004/jnccn.2025.7067.","pmid":"41671463","type":"DERIVED"},{"citation":"Seftel MD. Hyper-CVAD: a regimen for all seasons. Lancet Haematol. 2020 Jul;7(7):e501-e502. doi: 10.1016/S2352-3026(20)30179-4. No abstract available.","pmid":"32589970","type":"DERIVED"}],"start_date":{"date":"2019-06-24","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients","url":"https://clinicaltrials.gov/study/NCT03876769"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/cassiopeia-nct03876769"}